GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » Degree of Financial Leverage

Vera Therapeutics (Vera Therapeutics) Degree of Financial Leverage : 3.77 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Vera Therapeutics's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 3.77. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Vera Therapeutics's Degree of Financial Leverage or its related term are showing as below:

VERA's Degree of Financial Leverage is ranked worse than
93% of 1500 companies
in the Biotechnology industry
Industry Median: 0.96 vs VERA: 3.77

Vera Therapeutics Degree of Financial Leverage Historical Data

The historical data trend for Vera Therapeutics's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vera Therapeutics Degree of Financial Leverage Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
- 1.00 2.24 0.57 -6.78

Vera Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.45 -0.06 -6.78 3.77

Competitive Comparison of Vera Therapeutics's Degree of Financial Leverage

For the Biotechnology subindustry, Vera Therapeutics's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vera Therapeutics's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vera Therapeutics's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Vera Therapeutics's Degree of Financial Leverage falls into.



Vera Therapeutics Degree of Financial Leverage Calculation

Vera Therapeutics's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.05 (Mar. 2024) / -3.45 (Mar. 2023) - 1 )/( -89.484 (Mar. 2024) / -100.291 (Mar. 2023) - 1 )
=-0.4058/-0.1078
=3.77***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Vera Therapeutics  (NAS:VERA) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Vera Therapeutics Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Vera Therapeutics's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Vera Therapeutics (Vera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Executives
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Marshall Fordyce director, officer: President and CEO C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Celia Lin officer: Chief Medical Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley officer: Chief Development Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Sean Grant officer: Chief Financial Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg director
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Abingworth Bioventures 8 Lp 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Vera Therapeutics (Vera Therapeutics) Headlines